Fierce Biotech Fundraising Tracker ’25: CHARM attracts $80M; Wugen reels in $115M

CHARM Therapeutics secured an $80 million Series B funding round led by major investors including New Enterprise Associates, SR One, OrbiMed, F-Prime, Khosla Ventures, and NVIDIA14.

CHARM plans to use the funds to advance its AI-designed menin inhibitor into clinical trials for acute myeloid leukemia (AML) in the first quarter of 2026123.

The investigational menin inhibitor aims to treat AML at low doses without increasing the QTc interval and without inhibiting enzymes responsible for drug-drug interactions1.

NVIDIA is among the prominent backers of CHARM Therapeutics, highlighting the growing role of artificial intelligence in drug discovery14.

Wugen raised $115 million in a separate, significant funding round, reflecting strong investor interest in innovative biotech companies, though detailed purpose and investors for the Wugen round were not provided in the search results1.

Sources:

1. https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25

2. https://firstwordpharma.com/river/tag/fwmarketsegment/Artificial%20Intelligence

3. https://techfundingnews.com

4. https://www.pharmaceutical-technology.com/author/annabelkartalallen/